Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2020 - 2026)

Monte Rosa Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $328.3 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 2345150.0% year-over-year to $328.3 million; the TTM figure through Mar 2026 stood at $358.7 million (up 263.54% YoY), while the FY2025 annual figure was $30.4 million, down 69.31% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $328.3 million, up from $29.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $328.3 million in Q1 2026, with the low at -$217000.0 in Q3 2022.
• The 5-year median for Cash from Financing Activities is $365000.0 (2025), against an average of $29.7 million.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities sank 100.74% in 2022, then soared 2345150.0% in 2026.
• Monte Rosa Therapeutics' Cash from Financing Activities stood at $20.4 million in 2022, then increased by 23.19% to $25.2 million in 2023, then tumbled by 97.58% to $608000.0 in 2024, then jumped by 4772.37% to $29.6 million in 2025, then soared by 1008.34% to $328.3 million in 2026.
• Business Quant data shows GLUE's Cash from Financing Activities at $328.3 million in Q1 2026, $29.6 million in Q4 2025, and $348000.0 in Q3 2025.